1,000 gene carriers tracked to unlock amyloidosis secrets
NCT ID NCT05974644
First seen Jun 26, 2026 · Last updated Aug 13, 2026 · Updated 3 times
Summary
This study is a registry that will collect health information from 1,000 people who carry the gene for hereditary amyloidosis, including those with and without symptoms. Researchers will track who develops the disease and how it progresses, including the need for heart transplant or death. The goal is to better understand the condition and improve future care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this registry could help doctors predict who will develop hereditary amyloidosis and improve monitoring and early care for at-risk individuals.
- What could go wrong
- This is an observational registry, not a treatment trial. It will not test any new drug or therapy, so it cannot directly lead to a cure or symptom relief.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYLOIDOSIS, HEREDITARY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Virginia Commonwealth University
Richmond, Virginia, 23298, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Hidden heart risk: study aims to catch deadly protein buildup before symptoms start
- Hidden nerve disease found in carpal tunnel patients?
- Heart check: do Nerve-Targeting drugs also shield the heart in rare amyloidosis?
- Blood particles may reveal hidden heart disease
- Gene-Editing shot aims to halt rare nerve disease in phase 3 trial
- New shot every 3 months could slow rare nerve disease